146 related articles for article (PubMed ID: 16800736)
1. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins.
Obiezu CV; Michael IP; Levesque MA; Diamandis EP
Biol Chem; 2006 Jun; 387(6):749-59. PubMed ID: 16800736
[TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins.
Rajapakse S; Ogiwara K; Takano N; Moriyama A; Takahashi T
FEBS Lett; 2005 Dec; 579(30):6879-84. PubMed ID: 16337200
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic profiling of human kallikrein 14 using phage-display substrate technology.
Felber LM; Borgoño CA; Cloutier SM; Kündig C; Kishi T; Ribeiro Chagas J; Jichlinski P; Gygi CM; Leisinger HJ; Diamandis EP; Deperthes D
Biol Chem; 2005 Mar; 386(3):291-8. PubMed ID: 15843175
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site.
Debela M; Magdolen V; Grimminger V; Sommerhoff C; Messerschmidt A; Huber R; Friedrich R; Bode W; Goettig P
J Mol Biol; 2006 Oct; 362(5):1094-107. PubMed ID: 16950394
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 13 involvement in extracellular matrix degradation.
Kapadia C; Ghosh MC; Grass L; Diamandis EP
Biochem Biophys Res Commun; 2004 Oct; 323(3):1084-90. PubMed ID: 15381110
[TBL] [Abstract][Full Text] [Related]
6. The extracellular matrix protein fibronectin is a substrate for kallikrein 7.
Ramani VC; Haun RS
Biochem Biophys Res Commun; 2008 May; 369(4):1169-73. PubMed ID: 18343220
[TBL] [Abstract][Full Text] [Related]
7. Expression and enzymatic characterization of recombinant human kallikrein 14.
Rajapakse S; Takahashi T
Zoolog Sci; 2007 Aug; 24(8):774-80. PubMed ID: 18217483
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression.
Michael IP; Sotiropoulou G; Pampalakis G; Magklara A; Ghosh M; Wasney G; Diamandis EP
J Biol Chem; 2005 Apr; 280(15):14628-35. PubMed ID: 15713679
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12).
Memari N; Jiang W; Diamandis EP; Luo LY
Biol Chem; 2007 Apr; 388(4):427-35. PubMed ID: 17391064
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mouse glandular kallikrein 24 expressed in testicular Leydig cells.
Matsui H; Takano N; Takahashi T
Int J Biochem Cell Biol; 2005 Nov; 37(11):2333-43. PubMed ID: 15985384
[TBL] [Abstract][Full Text] [Related]
11. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.
Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
Prostate; 1998 Jan; 34(1):44-50. PubMed ID: 9428387
[TBL] [Abstract][Full Text] [Related]
12. Substrate specificity of Xenopus matrix metalloproteinase stromelysin-3.
Amano T; Fu L; Sahu S; Markey M; Shi YB
Int J Mol Med; 2004 Aug; 14(2):233-9. PubMed ID: 15254771
[TBL] [Abstract][Full Text] [Related]
13. 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding.
Laxmikanthan G; Blaber SI; Bernett MJ; Scarisbrick IA; Juliano MA; Blaber M
Proteins; 2005 Mar; 58(4):802-14. PubMed ID: 15651049
[TBL] [Abstract][Full Text] [Related]
14. Expression and characterization of human tissue kallikrein variants.
Chan H; Springman EB; Clark JM
Protein Expr Purif; 1998 Apr; 12(3):361-70. PubMed ID: 9535704
[TBL] [Abstract][Full Text] [Related]
15. alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein.
Heeb MJ; España F
Blood Cells Mol Dis; 1998 Dec; 24(4):412-9. PubMed ID: 9851894
[TBL] [Abstract][Full Text] [Related]
16. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14.
Borgoño CA; Michael IP; Shaw JL; Luo LY; Ghosh MC; Soosaipillai A; Grass L; Katsaros D; Diamandis EP
J Biol Chem; 2007 Jan; 282(4):2405-22. PubMed ID: 17110383
[TBL] [Abstract][Full Text] [Related]
17. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase.
Takayama TK; McMullen BA; Nelson PS; Matsumura M; Fujikawa K
Biochemistry; 2001 Dec; 40(50):15341-8. PubMed ID: 11735417
[TBL] [Abstract][Full Text] [Related]
18. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer.
Gao J; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Prostate; 2007 Mar; 67(4):348-60. PubMed ID: 17221837
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
Mize GJ; Wang W; Takayama TK
Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
[TBL] [Abstract][Full Text] [Related]
20. Characterization of mouse tissue kallikrein 5.
Rajapakse S; Ogiwara K; Yamano N; Kimura A; Hirata K; Takahashi S; Takahashi T
Zoolog Sci; 2006 Nov; 23(11):963-8. PubMed ID: 17189908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
